Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Perchloracap
Synonyms :
potassium perchlorate
Class :
Non-iodinated contrast media
Brand Name :
Perchloracap
Synonyms :
potassium perchlorate
Class :
Non-iodinated contrast media
Dosage forms and strengths Â
Oral capsule Â
250 mgÂ
Not indicatedÂ
Refer adult dosingÂ
They may diminish the serum concentration when combined with bile acid sequestrants
may decrease the diagnostic effect when combined with metyrapone
bladderwrack may lower the efficacy of antihyperthyroid medications
they decrease the efficacy of sodium iodide I-131 iodinated contrast agents
they decrease the efficacy of sodium iodide I-131 iodinated contrast agents
they decrease the efficacy of sodium iodide I-131 iodinated contrast agents
they decrease the efficacy of sodium iodide I-131 iodinated contrast agents
thyroid products decrease the concentration of cardiac glycosides in serum
thyroid products decrease the concentration of cardiac glycosides in serum
thyroid products decrease the concentration of cardiac glycosides in serum
they decrease the efficacy of sodium iodide I-131
they decrease the efficacy of sodium iodide I-131
it decreases the concentration of thyroid products in serum
may diminish the anticoagulant effect of Vitamin K Antagonist
may diminish the anticoagulant effect of Vitamin K Antagonist
may diminish the anticoagulant effect of Vitamin K Antagonist
may diminish the anticoagulant effect of Vitamin K Antagonist
may diminish the anticoagulant effect of Vitamin K Antagonist
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may reduce the anticoagulant effect
may reduce the anticoagulant effect
may reduce the anticoagulant effect
may reduce the anticoagulant effect
may reduce the anticoagulant effect
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the arrhythmogenic affect
may diminish the serum concentration when combined with thyroid products
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
estrogens esterified/methyltestosterone            Â
may decrease the therapeutic effect of estrogen derivatives
antacids: they may enhance the serum concentration of thyroid products
antacids: they may enhance the serum concentration of thyroid products
it decreases the concentration of thyroid products in serum
they decrease the effect of thyroid products
they decrease the effect of thyroid products
bazedoxifene/conjugated estrogens
they decrease the effect of thyroid products
they decrease the effect of thyroid products
they decrease the effect of thyroid products
it decreases the concentration of thyroid products in serum
it decreases the concentration of thyroid products in serum
it decreases the concentration of thyroid products in serum
it decreases the concentration of thyroid products in serum
thyroid products increase the effect of anticoagulation of vitamin K antagonists
thyroid products increase the effect of anticoagulation of vitamin K antagonists
thyroid products increase the effect of anticoagulation of vitamin K antagonists
thyroid products increase the effect of anticoagulation of vitamin K antagonists
thyroid products increase the effect of anticoagulation of vitamin K antagonists
may increase the absorption of Antacids
aluminum hydroxide/magnesium hydroxideÂ
may enhance the serum concentration of antacids
aluminum hydroxide/magnesium carbonateÂ
may enhance serum concentration of antacids
may decrease the levels of serum concentration of Cardiac Glycosides
may decrease the levels of serum concentration of Cardiac Glycosides
may decrease the levels of serum concentration of Cardiac Glycosides
may reduce the therapeutic effect of thyroid products
may reduce the therapeutic effect of thyroid products
cyproterone and ethinyl estradiolÂ
may decrease the therapeutic effect of Estrogen Derivatives
It may enhance the risk of adverse effects when combined with Mycolic acid inhibitors
It may enhance the risk of adverse effects when combined with Metabolic agents
It may enhance the risk of adverse effects when combined with Metabolic agents
It may enhance the risk of adverse effects when combined with Metabolic agents
It may enhance the risk of adverse effects when combined with Metabolic agents
It may enhance the risk of adverse effects when combined with Metabolic agents
amiodarone: they may decrease the therapeutic effect of thyroid products
tricyclic antidepressants may become more arrhythmogenic when used with thyroid products
tricyclic antidepressants may have a more stimulatory impact when used with thyroid products
abacavir leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
acetaminophen leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
aclidinium leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
acyclovir leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
allopurinol leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
almotriptan leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
alogliptin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
alprazolam leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
amantadine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
amoxicillin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
amphotericin b leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
ampicillin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
amrinone leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
ancestim leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
apremilast leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
arformoterol leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
arsenic trioxide leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
atazanavir leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
atomoxetine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
auranofin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
aurothioglucose leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
azacitidine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
azathioprine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
azelaic acid leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
aztreonam leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
bacitracin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
baclofen leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
benzatropine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
bepotastine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
bisoxatin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
bleomycin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
brivaracetam leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
bromazepam leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
budesonide leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
bupropion leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
buspirone leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
butabarbital leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
capecitabine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
carbidopa leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
carboplatin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
carmustine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefaclor leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefadroxil leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefalotin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefamandole leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefapirin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefazolin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefdinir leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefditoren leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefepime leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefmenoxime leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefmetazole leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefonicid leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
ceforanide leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefotaxime leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefotetan leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefotiam leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefoxitin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefpiramide leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefpirome leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefprozil leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefradine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
may decrease the concentration of thyroid products in serum
may decrease the concentration of thyroid products in serum
may decrease the concentration of thyroid products in serum
may decrease the concentration of thyroid products in serum
may decrease the concentration of thyroid products in serum
may decrease the concentration of thyroid products in serum
Actions and Spectrum:Â
Action:Â
Potassium perchlorate interferes with the normal functioning of the thyroid gland by competitively inhibiting the uptake of iodine. It blocks the sodium-iodide symporter in the thyroid gland, which is responsible for transporting iodine into the gland for the synthesis of thyroid hormones. Potassium perchlorate disrupts the production of thyroid hormones T3 & T4, essential for regulating metabolism and various biological functions.Â
Spectrum:Â Â
Potassium perchlorate has been historically used in some cases to temporarily lower thyroid hormone levels in adults with hyperthyroidism or to prevent the uptake of radioactive iodine in radiation emergencies.Â
Frequency not defined Â
Chest painÂ
TinglingÂ
WeaknessÂ
NauseaÂ
BleedingÂ
Severe throat irritationÂ
Nose and throat irritationÂ
Skin and eye irritationÂ
Black Box Warning:Â Â
None
Contraindication/Caution:Â Â
Hypersensitivity: People who are known to be allergic or hypersensitive to potassium perchlorate or related compounds should not use it due to the risk of allergic reactions.Â
Thyroid Disorders: Potassium perchlorate hinders the iodine absorption in the thyroid gland, potentially causing hypothyroidism or worsening pre-existing thyroid conditions like hyperthyroidism or goiter. therefore, individuals with thyroid conditions should avoid potassium perchlorate.Â
Pregnancy and Breastfeeding: Potassium perchlorate may offer risks to the developing foetus; its usage is generally contraindicated during pregnancy and nursing.Â
Renal Impairment: People with severe kidney problems should use potassium perchlorate with caution or avoid it altogether, as impaired kidney function may affect the clearance of the compound from the body, leading to potential toxicity.Â
Children: Potassium perchlorate is not recommended for use in children due to its potential effects on thyroid function and possible interference with growth and development.Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology: Potassium perchlorate is a chemical compound that has been used historically in the treatment of hyperthyroidism.Â
Pharmacodynamics:Â Â
Potassium perchlorate acts by competitively inhibiting the sodium-iodide symporter in the thyroid gland. This transporter is responsible for the intake of iodine by the thyroid follicular cells from the bloodstream, which is an essential step in the synthesis of thyroid hormones. By blocking this transporter, potassium perchlorate interferes because of the thyroid gland’s iodine buildup, thereby reducing the synthesis of thyroid hormones.Â
Pharmacokinetics:Â
AbsorptionÂ
Potassium perchlorate is absorbed rapidly from the gastrointestinal tract.Â
DistributionÂ
It is distributed widely throughout the body, including the thyroid gland.Â
MetabolismÂ
Potassium perchlorate does not undergo significant metabolism in the body.Â
Excretion and EliminationÂ
It is primarily eliminated through the kidneys via urine.Â
Administration: Â
The dosage and administration of potassium perchlorate in adults will depend on various factors, including the individual’s health condition, the specific medical need, and other medications they might be taking. Therefore, it’s crucial to follow the precise instructions provided by a qualified healthcare provider.Â
Patient information leafletÂ
Generic Name: potassium perchlorateÂ
Why do we use potassium perchlorate? Â
Potassium perchlorate has been historically used in the treatment of hyperthyroidism. It works by blocking the uptake of iodine by the thyroid gland, thereby reducing the production of thyroid hormones. However, its use in medical treatments has declined because of possible adverse effects and the existence of safer substitutes.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
